Chronic Low Back Pain Clinical Trial
Official title:
The IMPACT of a Referral Model for Axial Spondyloarthritis in Young Patients With Chronic Low Back Pain - a Cluster Randomized Trial
Rationale: Axial spondyloarthritis (axSpA) is an inflammatory back pain disorder affecting
up to 24% of young chronic low back pain (CLBP) patients. For general practitioners (GPs) it
is difficult to distinguish axSpA patients in the large amount of CLBP patients. In previous
studies a referral rule for axSpA applicable in CLBP patients was developed and validated.
The next step is to investigate the impact of the referral rule in daily practice. This
impact analysis will test if the referral rule will be beneficial or harmful.
Objective: To evaluate the clinical impact of a referral rule in young patients presenting
at the general practitioners with chronic low back pain, who are at risk for axSpA, compared
to usual care.
Study design: A cluster randomized clinical trial. Study population: Primary care patients
with chronic low back pain, aged 18-45 years.
Intervention (if applicable): GPs are randomized in clusters either to use directly the
referral rule or use the referral rule after 4 months. The referral rule consists out of
four variables, a positive ASAS inflammatory back pain questionnaire, a positive family
history for spondyloarthritis, a good reaction to NSAIDs (non-steroidal anti-inflammatory
drugs) and back pain duration longer than 5 years. If at least two out of four variables are
present a referral to the rheumatologist is advised.
Main study parameters/endpoints: The primary outcome is a change in the Roland Morris
Disability Questionnaire (RMDQ) compared to baseline in the CLBP patients with or without
use of the referral model.
Secondary parameters: Quality of life measurements, cost-effectiveness, pain and fatigue and
referral to rheumatologist and diagnosis of axSpA.
Nature and extent of the burden and risks associated with participation, benefit and group
relatedness:
The burden and risks associated with participation are minimal. No medical intervention is
taken place. If the GP of the patients is randomized to the referral model, the patient is
checked for the risk of axial spondyloarthritis, by the non-invasive referral model. If the
referral model is positive a referral to the rheumatologist is advised. Is the GP is
randomized to the 'usual care' there is no difference in the treatment of low back pain than
nowadays. A GP is still allowed to treat the CLBP patients optimal and a referral to the
rheumatologist is allowed but not actively advised.
All participating CLBP patients are asked to fill several questionnaires at four different
time points, at baseline, after 12 months and after 24 months. In total there are 8
questionnaires and four separate questions. The questionnaire are designed to fill out by
the patient themselves. The total time to fill in the questionnaire is estimated to be 30
minutes.
The benefits of the study are:
- For the CLBP patients, up to 24% of the back pain complaints are caused by axSpA, but
the GPs are not (yet) aware of this disease. When a CLBP patient is participating in
this study, the chance of having axSpA as cause for the back pain is investigated. This
a benefit for a CLBP patients since there is effective treatment for axSpA.
- For the GP it is very difficult to distinguish an axSpA patients in the large amount of
CLBP patients. If it appears that the validated referral rule has an impact on CLBP and
GPs, the next step will be implementation of this referral model in daily practice and
it will become a helpful tool for the GP.
- For the society, CLBP is a great socioeconomic burden for the society. When one of the
causes for CLBP, namely axSpA is diagnosed and treated in an earlier stage this will
lead to a decreased sick leave because of back pain and is therefore potentially
cost-effective.
n/a
Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03243084 -
Transcranial Alternating Current Stimulation in Back Pain- Pilot Sudy
|
N/A | |
Suspended |
NCT04735185 -
Stem Cells vs. Steroids for Discogenic Back Pain
|
N/A | |
Completed |
NCT03162952 -
RAND Center of Excellence for the Study of Appropriateness of Care in CAM
|
||
Completed |
NCT03240146 -
Pulsed Shortwave Therapy Treatment for Chronic Musculoskeletal Low Back Pain
|
N/A | |
Completed |
NCT05282589 -
Lumbopelvic Manipulation Effects on Fatigue in Chronic Low Back Pain Patients
|
N/A | |
Completed |
NCT03637998 -
Physical Activity on Neurophysiologic Gene Expression Profiles of Chronic Low Back Pain
|
N/A | |
Recruiting |
NCT02289170 -
Clinical Study to Evaluate the Safety and Efficacy of Heating and Cooling Combination Therapeutic Device(OCH-S100)
|
N/A | |
Completed |
NCT02231554 -
Feldenkrais vs Back School for Treating Chronic Low Back Pain: a Randomized Controlled Trial
|
N/A | |
Recruiting |
NCT02063503 -
Identification of Prognostic Indicators for Rehabilitation in Chronic Nonspecific Low Back Pain Patients
|
N/A | |
Terminated |
NCT01620775 -
MR(Magnetic Resonance) Imaging of Neurotransmitters in Chronic Pain
|
N/A | |
Completed |
NCT01704677 -
Lumbar Disc Prosthesis Versus Multidisciplinary Rehabilitation; 8-year Follow-up
|
N/A | |
Completed |
NCT01177280 -
Prevalence of Potential Cytochrome P450 Pharmacokinetic Incident Drug-Drug Interactions Among Chronic Low Back Pain Patients Taking Opioid Analgesics and Associated Economic Outcomes
|
N/A | |
Completed |
NCT01177254 -
Exposure to Potential Cytochrome P450 Pharmacokinetic Drug-Drug Interactions Among Osteoarthritis Patients: Incremental Risk of Multiple Prescriptions
|
N/A | |
Completed |
NCT01177241 -
Cytochrome P450 Pharmacokinetic DDIs Among Patients With Chronic Low Back Pain Taking Opioids
|
N/A | |
Completed |
NCT01490905 -
A Double Blind Placebo Study to Determine the Effectiveness of Theramine on the Management of Chronic Back Pain
|
Phase 4 | |
Completed |
NCT00984815 -
Safety Study of HZT-501 in Patients Who Require Long-Term Daily Non-steroidal Anti-inflammatory Drug Treatment
|
Phase 3 | |
Completed |
NCT00763321 -
Study to Evaluate the Safety and Efficacy of ABT-712 in Subjects With Moderate to Severe Chronic Low Back Pain (CLBP)
|
Phase 3 | |
Completed |
NCT00761150 -
Study to Evaluate the Safety and Efficacy of ABT-712 in Subjects With Moderate to Severe Chronic Low Back Pain (CLBP)
|
Phase 3 | |
Completed |
NCT00767806 -
A Study for Patient With Chronic Low Back Pain
|
Phase 3 | |
Completed |
NCT00613106 -
Double-Blind Follow-on Safety Study of HZT-501 (Ibuprofen 800 mg/Famotidine 26.6 mg) in Subjects Who Have Completed Participation in HZ-CA-301 (NCT00450658) or HZ-CA-303 (NCT00450216)
|
Phase 3 |